Note: All changes are versus the prior-year period unless otherwise stated
"Takeda’s first-quarter results demonstrate the continued strength of our 14 global brands and, with the business momentum from this strong start to our fiscal year, we remain on track towards our full-year management guidance," remarked chief financial officer Costa Saroukos.
The company's quarterly profit gained a boost after it sold a portfolio of type 2 diabetes products in Japan to Teijin Pharma for JPY 133 billion ($1.2 billion).
Takeda continues to expect mid-single-digit revenue growth in fiscal year 2021 to JPY 3.4 trillion ($31 billion), with profit of JPY 250 billion ($2.3 billion).
To read more Top Story articles, click here.